Literature DB >> 21521772

Type 1 diabetes-induced hyper-responsiveness to 5-hydroxytryptamine in rat pulmonary arteries via oxidative stress and induction of cyclooxygenase-2.

Jose G Lopez-Lopez1, Javier Moral-Sanz, Giovanna Frazziano, Maria J Gomez-Villalobos, Laura Moreno, Carmen Menendez, Jorge Flores-Hernandez, Jose A Lorente, Angel Cogolludo, Francisco Perez-Vizcaino.   

Abstract

Recent epidemiological data suggest that diabetes is a risk factor for pulmonary arterial hypertension. The aim of the present study was to analyze the link between type 1 diabetes and pulmonary arterial dysfunction in rats. Male Sprague-Dawley rats were randomly divided into a control group (saline) and a diabetic group (70 mg/kg streptozotocin). After 6 weeks, diabetic animals showed a down-regulation of the lung bone morphogenetic protein receptor type 2, up-regulation of 5-hydroxytryptamine (5-HT) 2A receptors and cyclooxygenase-2 (COX-2) proteins as measured by Western blot analysis, and increased contractile responses to 5-HT in isolated intrapulmonary arteries. The hyper-responsiveness to 5-HT was endothelium-independent and unaffected by inhibition of nitric-oxide synthase but prevented by indomethacin, the selective COX-2 inhibitor N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methane sulfonamide (NS-398), superoxide dismutase, and the NADPH oxidase inhibitor apocynin or chronic treatment with insulin. However, diabetic rats at 6 weeks did not develop elevated right ventricular pressure or pulmonary artery muscularization, whereas a longer exposure (4 months) to diabetes induced a modest, but significant, increase in right ventricular systolic pressure. In conclusion, type 1 diabetes mellitus in rats induces a number of changes in lung protein expression and pulmonary vascular reactivity characteristic of clinical and experimental pulmonary arterial hypertension but insufficient to elevate pulmonary pressure. Our results further strengthen the link between diabetes and pulmonary arterial hypertension.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21521772     DOI: 10.1124/jpet.111.179515

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

Review 1.  Constrictor prostanoids and uridine adenosine tetraphosphate: vascular mediators and therapeutic targets in hypertension and diabetes.

Authors:  Takayuki Matsumoto; Styliani Goulopoulou; Kumiko Taguchi; Rita C Tostes; Tsuneo Kobayashi
Journal:  Br J Pharmacol       Date:  2015-07-08       Impact factor: 8.739

Review 2.  Pulmonary vascular dysfunction in metabolic syndrome.

Authors:  Conor Willson; Makiko Watanabe; Atsumi Tsuji-Hosokawa; Ayako Makino
Journal:  J Physiol       Date:  2018-09-12       Impact factor: 5.182

3.  Cyclooxygenase 2, toll-like receptor 4 and interleukin 1β mRNA expression in atherosclerotic plaques of type 2 diabetic patients.

Authors:  Alessandro Baldan; Silvia Ferronato; Silvia Olivato; Giovanni Malerba; Alberto Scuro; Gian Franco Veraldi; Matteo Gelati; Sergio Ferrari; Sara Mariotto; Pier Franco Pignatti; Sara Mazzucco; Macarena Gomez-Lira
Journal:  Inflamm Res       Date:  2014-08-06       Impact factor: 4.575

Review 4.  Endothelial and Smooth Muscle Cell Interactions in the Pathobiology of Pulmonary Hypertension.

Authors:  Yuansheng Gao; Tianji Chen; J Usha Raj
Journal:  Am J Respir Cell Mol Biol       Date:  2016-04       Impact factor: 6.914

5.  Impaired right ventricular hemodynamics indicate preclinical pulmonary hypertension in patients with metabolic syndrome.

Authors:  Deepa M Gopal; Rajalakshmi Santhanakrishnan; Yi-Chih Wang; Nir Ayalon; Courtney Donohue; Youssef Rahban; Alejandro J Perez; Jill Downing; Chang-seng Liang; Noyan Gokce; Wilson S Colucci; Jennifer E Ho
Journal:  J Am Heart Assoc       Date:  2015-03-10       Impact factor: 5.501

6.  The flavonoid quercetin reverses pulmonary hypertension in rats.

Authors:  Daniel Morales-Cano; Carmen Menendez; Enrique Moreno; Javier Moral-Sanz; Bianca Barreira; Pilar Galindo; Rachele Pandolfi; Rosario Jimenez; Laura Moreno; Angel Cogolludo; Juan Duarte; Francisco Perez-Vizcaino
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

7.  Obesity and pulmonary hypertension: a review of pathophysiologic mechanisms.

Authors:  Scott E Friedman; Bruce W Andrus
Journal:  J Obes       Date:  2012-09-03

8.  Fenofibrate improves vascular endothelial function and contractility in diabetic mice.

Authors:  Nan Xu; Qin Wang; Shan Jiang; Qijing Wang; Weipeng Hu; Suhan Zhou; Liang Zhao; Lanyu Xie; Jianghua Chen; Anton Wellstein; En Yin Lai
Journal:  Redox Biol       Date:  2018-10-01       Impact factor: 11.799

9.  Comparison of Pulmonary and Systemic NO- and PGI2-Dependent Endothelial Function in Diabetic Mice.

Authors:  Andrzej Fedorowicz; Elżbieta Buczek; Łukasz Mateuszuk; Elzbieta Czarnowska; Barbara Sitek; Agnieszka Jasztal; Antonina Chmura-Skirlińska; Mobin Dib; Sebastian Steven; Andreas Daiber; Stefan Chlopicki
Journal:  Oxid Med Cell Longev       Date:  2018-06-04       Impact factor: 6.543

10.  Elevated pulmonary arterial pressure in Zucker diabetic fatty rats.

Authors:  Daniel Morales-Cano; Maria Callejo; Bianca Barreira; Gema Mondejar-Parreño; Sergio Esquivel-Ruiz; Sonia Ramos; María Ángeles Martín; Angel Cogolludo; Laura Moreno; Francisco Perez-Vizcaino
Journal:  PLoS One       Date:  2019-01-28       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.